Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2024-06-03 Environmental & Social …
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Ocena skuteczności 1-MNA w łuszczycy - Content (PL)
Environmental & Social Information Classification · 99% confidence The document text describes a specific agreement (umowa) entered into by the Management Board (Zarząd) of PHARMENA S.A. to conduct a research project (Proof of Concept study) regarding 1-methylnicotinamide (1-MNA) for psoriasis treatment. This relates to the company's operational development and future product pipeline, which is a strategic business matter. It is not a standard financial report (10-K, IR, ER), a management change (MANG), or a director's trade (DIRS). Since it details a significant business development that impacts future prospects, it best fits under general strategic or operational updates. Given the provided categories, this type of announcement about a new research collaboration and its potential impact on future development is most closely aligned with a general strategic/operational update, which often falls under Regulatory Filings (RNS) if no more specific category applies, or potentially a general business update. However, since it is a specific announcement about a material business agreement impacting future development, and it is not a standard financial filing, RNS (Regulatory Filings) serves as the most appropriate general category for material, non-standard announcements.
2024-06-03 Polish
Pharmena Raport I kwartał 2024
Interim / Quarterly Report Classification · 100% confidence The document is a table of contents for a 'Śródroczny skrócony skonsolidowany raport kwartalny' (Interim condensed consolidated quarterly report) for the period ending March 31, 2024. It contains detailed sections on financial statements (balance sheet, income statement, cash flow, etc.) and management notes. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. Q1 2024
2024-05-24 Polish
Zakończenie prac koncepcyjnych innowacyjnego wyrobu medycznego do stosowania w trudno gojących się ranach - Content (PL)
Report Publication Announcement Classification · 99% confidence The document is a short announcement (1512 characters) written in Polish, referencing a previous current report ('raport bieżący nr 17/2023'). It details the completion of the conceptual phase for developing an innovative medical device for hard-to-heal wounds and states that the Issuer ('Emitent') will inform about subsequent stages via current reports. This structure—a brief update on an ongoing project, referencing prior disclosures, and promising future updates—is characteristic of a general regulatory announcement that doesn't fit a specific financial reporting category (like 10-K, ER, or IR). Since it is a regulatory update that doesn't fit the more specific categories (like DIRS, DIV, MANG, etc.), the most appropriate fallback category is Regulatory Filings (RNS).
2024-05-16 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na ZWZ w dniu 03.04.2024 r. - Content (PL)
AGM Information Classification · 99% confidence The document text is very short (398 characters) and explicitly states that the Management Board ('Zarząd') is presenting an attached list ('w załączeniu wykaz') of shareholders holding at least 5% of the votes at the Annual General Meeting ('Zwyczajnym Walnym Zgromadzeniu') held on 03.04.2024. This content—announcing the publication of specific voting-related data from a general meeting—is a regulatory announcement rather than the full report itself. Since the document is an announcement about published results/data from a shareholder meeting, it fits best under the 'Declaration of Voting Results & Voting Rights Announcements' (DVA) category, as it details the voting structure post-meeting. It is not a general regulatory filing (RNS) because DVA is more specific to voting outcomes.
2024-04-05 Polish
Powołanie członków Rady Nadzorczej na nową kadencję - Content (PL)
Board/Management Information Classification · 98% confidence The document text, written in Polish, explicitly states that the Management Board (Zarząd) of PHARMENA S.A. informs about the Ordinary General Meeting (Zwyczajne Walne Zgromadzenie) held on April 3, 2024. The key resolution mentioned (uchwałę nr 22) concerns the appointment of the Supervisory Board (Rady Nadzorczej) for a new term due to the expiration of the previous term. This directly relates to changes in the company's governing body. This aligns perfectly with the definition of Board/Management Information (MANG): 'Announcement of changes in the company's board of directors or senior management.' The document also mentions that detailed information about the appointed members is provided in the attachments, but the core announcement is the appointment itself.
2024-04-03 Polish
Wypłata dywidendy - Content (PL)
Notice of Dividend Amount Classification · 99% confidence The document explicitly states that the Management Board (Zarząd) of PHARMENA S.A. is informing about a resolution passed during the Ordinary General Meeting (Zwyczajne Walne Zgromadzenie) on April 3, 2024. Resolution No. 13 concerns the allocation of undistributed profits for the payment of a dividend. The text details the total amount allocated (9,467,094.30 PLN), the dividend per share (0.85 PLN), the record date (April 10, 2024), and the payment date (April 24, 2024). This content directly relates to the announcement of a dividend amount and details, matching the definition for 'Notice of Dividend Amount' (DIV). Although an AGM took place, the core subject of this specific announcement is the dividend decision, not general AGM materials or voting results.
2024-04-03 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.